Atlas Trials

Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma.

Clinical trial NCT06574412 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06574412
Sponsor
The First Hospital of Jilin University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Resectable Clear Cell Carcinoma of the Kidney
Start date
2024-09-01
Primary completion
2027-08-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.